Drug Class Review: Second-Generation Antidepressants - Update 5 The Drug Effectiveness Review Project

Description

Key Questions 1. For outpatients with depressive, anxiety, and/or premenstrual dysphoric disorders, do second-generation antidepressants differ in efficacy or effectiveness? 2. For outpatients with depressive, anxiety, and/or premenstrual dysphoric disorders, do second-generation antidepressants differ in harms or adverse events? 3. Are there subgroups of patients based on demographics (age, racial groups, socio-demographic factors, and sex), other medications, or comorbidities for which one second-generation antidepressant is more effective or associated with fewer adverse events than another?

Details

Duration 01/07/2009 - 31/03/2011
Funding Sonstige
Department

Department for Evidence-based Medicine and Evaluation

Principle investigator for the project (Danube University Krems) Univ.-Prof. Dr. Gerald Gartlehner, MPH
Project members Dr. Angela Kaminski-Hartenthaler Mag. Christina Kien Michaela Strobelberger, MA Dipl.-Ing. Patricia Tüchler

Publications

Gartlehner, G.; Reichenpfader, U.; Kaminski, A.; Kien, C.; Thaler, K. et. al. (2011). Drug Class Review: Second-generation Antidepressants: Final Update 5 Report. Oregon Health & Science University, http://www.ncbi.nlm.nih.gov/books/NBK54355/pdf/TOC.pdf

Team

Back to top

 

To Glossary

This website uses cookies to improve your user experience, for analytical purposes for optimizing our systems and for marketing purposes. By clicking on „OK" or continuing to browse the site, you are agreeing to the use of cookies. More information concerning privacy policy and data protection official.

OK